Retrospective Analysis of Hairy Cell Leukemia Patients Treated with Different Modalities as First Line: Real-Life Experience Over 20 years

Basit Öğe Kaydı
dc.contributor.authorYilmaz, Fergun
dc.contributor.authorAtilla, Dilan
dc.contributor.authorAkkas, Nagihan
dc.contributor.authorBulbul, Hale
dc.contributor.authorSoyer, Nur
dc.contributor.authorDemir, Derya
dc.contributor.authorPayzin, Bahriye
dc.date.accessioned2020-12-01T12:09:10Z
dc.date.available2020-12-01T12:09:10Z
dc.date.issued2019
dc.departmentEge Üniversitesien_US
dc.descriptionSahin, Fahri/0000-0001-9315-8891en_US
dc.description.abstractWe aimed to analyze the characteristics and response rates of different treatment modalities in hairy cell leukemia patients over 20 diagnosed as hairy cell leukemia (HCL). Clinical data, response rates and survival outcome of the patients who were diagnosed with HCL were retrospectively analyzed. Fifty-two patients with a median age of 50 (28-87) years were enrolled in the study. 38 patients (73%) were male and male to female ratio was 2.7. First line therapy was cladrabine in 36 patients (69.2%). the overall response rate was 97%. CR and PR rates were 86.1% and 11.1%, respectively. Interferon was used in 10(19.2%) patients who were diagnosed before 2000s years. CR and PR rates were 70% and 30%, respectively. Although the CR rates were lower in IFN group, this difference could not be reached statistically significance (p = 0.24). the median follow up was 48 months (12-252). the median OS was not reached and median PFS was 150 months (95% CI, 116-214). the OS at 36 and 48 months were 95.9% and 92.3%, respectively and the PFS at 36 and 48 months were 90.2% and 83.4%, respectively. After the introduction of purine analogues, the fate of the HCL patients have been changed. Cladrabin achieved very high response rates in both young and older patients, in our study. Although relapse still constitutes a problem, another single dose of cladrabine results in good response rates.en_US
dc.identifier.doi10.1007/s12288-019-01132-7
dc.identifier.endpage698en_US
dc.identifier.issn0971-4502
dc.identifier.issn0974-0449
dc.identifier.issue4en_US
dc.identifier.pmid31741621en_US
dc.identifier.startpage692en_US
dc.identifier.urihttps://doi.org/10.1007/s12288-019-01132-7
dc.identifier.urihttps://hdl.handle.net/11454/63345
dc.identifier.volume35en_US
dc.identifier.wosWOS:000493658300012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Indiaen_US
dc.relation.ispartofIndian Journal of Hematology and Blood Transfusionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHairy cell leukemiaen_US
dc.subjectCladrabinen_US
dc.subjectTreatmenten_US
dc.subjectSurvival ratesen_US
dc.subjectResponse ratesen_US
dc.titleRetrospective Analysis of Hairy Cell Leukemia Patients Treated with Different Modalities as First Line: Real-Life Experience Over 20 yearsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu